🔗 Permalink

Inventor profile of:

Vanitha RAMAKRISHNAN

City:

Belmont, California

Country:

United States

Published Applications:

Last publication date:

2025-06-19

Top Assignees for applications by Vanitha RAMAKRISHNAN

The entities that hold a legal rights for patent applications filed by inventor RAMAKRISHNAN Vanitha:

PDL BIOPHARMA, INC. 7 Fremont, CA United States
FACET BIOTECH CORPORATION 6 Redwood City, CA United States
Abbott Biotherapeutics Corp. 4 Redwood City, CA United States
Millennium Pharmaceuticals, Inc. 2 Cambridge, MA United States
Harpoon Therapeutics, Inc. 2 South San Francisco, CA United States
PDL BioPharma, Inc. 2 Redwood City, CA United States
FACET BIOTECH 1 REDWOOD CITY, CA United States
Protein Design Labs, Inc. 1 Fremont, CA United States
HARPOON THERAPEUTICS, INC. 1 Brisbane, CA United States
Facet Biotech Corporation 1 Redwood, CA United States

Recent patent applications by RAMAKRISHNAN Vanitha

Vanitha RAMAKRISHNAN from Belmont, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-06-19

US20250197526A1

Chemistry; metallurgy

TRISPECIFIC BINDING PROTEINS AND METHODS OF USE

#2 | 2021-06-17

US20210179735A1

Chemistry; metallurgy

Trispecific binding proteins and methods of use

#3 | 2017-10-19

US20170298149A1

Chemistry; metallurgy

Trispecific binding proteins and methods of use

#4 | 2016-11-24

US20160340444A1

Chemistry; metallurgy

Trispecific binding proteins and methods of use

#5 | 2011-12-08

US20110300133A1

Chemistry; metallurgy

Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis

#6 | 2011-02-17

US20110038864A1

Chemistry; metallurgy

Antibodies against cancer antigen TMEFF2 and uses thereof

#7 | 2010-11-18

US20100291111A1

Chemistry; metallurgy

Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation

#8 | 2009-10-15

US20090259031A1

Chemistry; metallurgy

Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis

#9 | 2009-02-12

US20090041767A1

Chemistry; metallurgy

PHARMACEUTICAL COMBINATIONS

#10 | 2008-10-23

US20080260740A1

Chemistry; metallurgy

Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer

#11 | 2008-10-23

US20080260732A1

Chemistry; metallurgy

Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis

#12 | 2008-07-31

US20080181903A1

Chemistry; metallurgy

CONJUGATE OF NATRIURETIC PEPTIDE AND ANTIBODY CONSTANT REGION

#13 | 2008-07-24

US20080175846A1

Chemistry; metallurgy

Antibodies against cancer antigen TMEFF2 and uses thereof

#14 | 2008-07-03

US20080160012A1

Chemistry; metallurgy

Antibodies against cancer antigen TMEFF2 and uses thereof

#15 | 2008-02-21

US20080044840A1

Chemistry; metallurgy

Antibodies against cancer antigen TMEFF2 and uses thereof

#16 | 2008-01-31

US20080026458A1

Chemistry; metallurgy

Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis

#17 | 2008-01-31

US20080026033A1

Chemistry; metallurgy

Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis

#18 | 2007-10-30

US10383447

Antibodies against cancer antigen TMEFF2 and uses thereof

#19 | 2006-06-13

US9003810

Inhibitory immunoglobulin polypeptides to human PDGF beta receptor

#20 | 2006-01-12

US20060008415A1

Human necessities

Stable liquid and lyophilized formulation of proteins

#21 | 2005-11-24

US20050260212A1

Chemistry; metallurgy

Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer

#22 | 2005-11-24

US20050260210A1

Chemistry; metallurgy

Use of anti-α5β1 antibodies to inhibit cancer cell proliferation

#23 | 2005-10-11

US9775803

Transgenic animals having a modified glycoprotein V gene

#24 | 2005-07-28

US20050163769A1

Chemistry; metallurgy

Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis

#25 | 2005-03-10

US20050054834A1

Chemistry; metallurgy

Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis

InventorID:

1717323 ⎘